These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7248031)

  • 21. Nigro-striatal pathway: stimulation-evoked release of ( 3 H)dopamine from caudate nucleus.
    Voigtlander PF; Moore KE
    Brain Res; 1971 Dec; 35(2):580-3. PubMed ID: 5135554
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of ventromedial tegmental lesions on the disposition of dopamine in the caudate nucleus of the monkey.
    Goldstein M; Anagnoste B; Owen WS; Battista AF
    Brain Res; 1967 Mar; 4(2):298-300. PubMed ID: 4961813
    [No Abstract]   [Full Text] [Related]  

  • 23. Involvement of nigro-striatal neurons in the in vivo release of dopamine by amphetamine, amantadine and tyramine.
    Von Voigtlander PF; Moore KE
    J Pharmacol Exp Ther; 1973 Mar; 184(3):542-52. PubMed ID: 4687219
    [No Abstract]   [Full Text] [Related]  

  • 24. Uptake of tyramine into synaptic vesicles of the caudate nucleus.
    Lentzen H; Philippu A
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Oct; 300(1):25-30. PubMed ID: 339111
    [No Abstract]   [Full Text] [Related]  

  • 25. The ontogeny of amphetamine-induced dopamine release in the caudate-putamen of the rat.
    Gazzara RA; Fisher RS; Howard SG
    Brain Res; 1986 Aug; 393(2):213-20. PubMed ID: 3742239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Release to the cerebral ventricles of substances with possible transmitter function in the caudate nucleus.
    Portig PJ; Vogt M
    J Physiol; 1969 Oct; 204(3):687-715. PubMed ID: 4309959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proceedings: Tyraminergic mechanisms in rat striatum.
    Boulton AA; Juorio AV; Phillips SR; Wu PH
    Br J Pharmacol; 1975 Oct; 55(2):296P-297P. PubMed ID: 1201423
    [No Abstract]   [Full Text] [Related]  

  • 28. Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration.
    Kwok RP; Juorio AV
    Neuroendocrinology; 1986; 43(5):590-6. PubMed ID: 3528901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
    Bokobza B; Ruberg M; Scatton B; Javoy-Agid F; Agid Y
    Eur J Pharmacol; 1984 Mar; 99(2-3):167-75. PubMed ID: 6734727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased sensitivity of caudatal neurons to microiontophoretic dopamine in dopamine-depleted caudate nucleus.
    Norcross K; Spehlmann R
    Brain Res; 1978 Nov; 156(1):175-80. PubMed ID: 698832
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolism of dopamine in the substantia nigra after antidromic activation.
    Korf J; Zieleman M; Westerink BH
    Brain Res; 1977 Jan; 120(1):184-7. PubMed ID: 832118
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of chronically administered L-dopa in normal and lesioned cats.
    Langelier P; Roberge AG; Boucher R; Poirier LJ
    J Pharmacol Exp Ther; 1973 Oct; 187(1):15-26. PubMed ID: 4746324
    [No Abstract]   [Full Text] [Related]  

  • 33. Uptake of para-tyramine and meta-tyramine into slices of the caudate nucleus and hypothalamus of the rat.
    Petrali EH; Boulton AA; Dyck LE
    Neurochem Res; 1979 Oct; 4(5):633-42. PubMed ID: 492450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the immunoneutralization of substance P in the cat substantia nigra on the release of dopamine from dendrites and terminals of dopaminergic neurons.
    Cheramy A; Michelot R; Leviel V; Nieoullon A; Glowinski J; Kerdelhue B
    Brain Res; 1978 Oct; 155(2):404-8. PubMed ID: 688024
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of L-DOPA on the synthesis and excretion of tyramine.
    Boulton AA; Wu PH
    Adv Neurol; 1974; 5():119-25. PubMed ID: 4613157
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of reserpine and 6-hydroxydopamine on the concentrations of some arylakylamines in rat brain.
    Boulton AA; Juorio AV; Philips SR; Wu PH
    Br J Pharmacol; 1977 Jan; 59(1):209-14. PubMed ID: 837000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Release of endogenously synthesized catechols from the caudate nucleus by stimulation of the nigro-striatal pathway and by the administration of d-amphetamine.
    Chiueh CC; Moore KE
    Brain Res; 1973 Feb; 50(1):221-5. PubMed ID: 4690549
    [No Abstract]   [Full Text] [Related]  

  • 38. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 39. Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra.
    Dentresangle C; Le Cavorsin M; Savasta M; Leviel V
    Brain Res; 2001 Mar; 893(1-2):178-85. PubMed ID: 11223005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo spontaneous and evoked release of newly synthesized dopamine in the cat caudate nucleus.
    Besson MJ; Cheramy A; Gauchy C; Glowinski J
    Adv Neurol; 1974; 5():69-78. PubMed ID: 4155237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.